Grant: Alliance Grants
University of Guelph
$72,792.00
Harnessing the Power of Cannabinoids to Reverse Cannabis-induced Toxicosis in Pets._x000d_
FY 2020-21
Summary
The legalization of cannabis in Canada, combined with the changing attitudes towards cannabis, have resulted in increases in both intentional and unintentional exposures to cannabis in pets. Signs that an animal has been exposed to cannabis generally include depression, ataxia, mydriasis, abnormal startle, acoustic hypersensitivity, bradycardia, hypothermia, urinary incontinence, and although rare, even death.This proposal aims to tackle the issue of cannabis-associated toxicity (usually due to the presence of delta-9-tetrahydrocannabinol [THC]) in pets and to test novel therapeutic avenues toward reducing toxicosis-related harms, from both intentional and accidental exposure. Current treatment options include monitoring and decontamination, therefore underscoring the need for novel pharmacological treatments. The industry sponsor/partner for this collaboration is Avicanna Inc., a biopharmaceutical company solely devoted to the development of cannabinoid-based medicinal products since its inception. In partnership with Dr. Khokhar, with his extensive track-record in behavioural pharmacology, this collaboration aims to provide a deeper understanding of the neural basis of cannabis-induced toxicosis in pets as well as the potential utility of cannabis-derived compounds and formulations for aiding the treatment of cannabis-induced toxicosis in pets. The goal of this series of experiments is to first establish the behavioural and neural correlates of cannabis-toxicosis in a rat model, and then test the effects of cannabidiol and tetrahydrocannabivarin (both agents can counteract the effect of THC), both alone and in combination on THC-induced toxicosis. The specific aims for this study are as follows:
Aim 1: To determine the behavioural and neural correlates of acute high-dose THC exposure via edible and vapour routes of administration.
Aim 2: To determine whether cannabidiol or THCV treatment, either alone or in combination, reduce the magnitude of the behavioural and neural correlates of acute high-dose THC toxicosis.
The findings from these studies will be impactful since they will identify a potentially novel therapeutic avenue for reducing THC-induced toxicosis in pets, as well as establishing the neural correlates of THC-induced toxicosis.
Program
Alliance Grants
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data
As published
Application id
549529-2019
Name nom
Khokhar, Jibran
Department département
Biomedical Sciences
Organization id
24
Institution établissement
University of Guelph
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2020
Competition year année de concours
2019
Award amount
72792
Program id
ALLRP
Program name en
Alliance Grants
Program name fr
Subventions Alliance
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
96
Committee name en
RPP Internal Decision Cttee
Committee name fr
Cté de décision interne - PPR
Area of application code
505
Area of application group en
Manufacturing processes and products
Area of application group fr
Procédés et produits industriels
Area of application en
Veterinary pharmaceuticals
Area of application fr
Produits pharmaceutiques à usage vétérinaire
Research subject code
5512
Research subject group en
Animal biology
Research subject group fr
Biologie animale
Research subject en
Veterinary sciences
Research subject fr
Médecine vétérinaire
Installment
inst:1 - 1
Partie
1
Nb partie
1
Application title
Harnessing the Power of Cannabinoids to Reverse Cannabis-induced Toxicosis in Pets._x000d_
Keyword
NSERC
Application summary
The legalization of cannabis in Canada, combined with the changing attitudes towards cannabis, have resulted in increases in both intentional and unintentional exposures to cannabis in pets. Signs that an animal has been exposed to cannabis generally include depression, ataxia, mydriasis, abnormal startle, acoustic hypersensitivity, bradycardia, hypothermia, urinary incontinence, and although rare, even death.This proposal aims to tackle the issue of cannabis-associated toxicity (usually due to the presence of delta-9-tetrahydrocannabinol [THC]) in pets and to test novel therapeutic avenues toward reducing toxicosis-related harms, from both intentional and accidental exposure. Current treatment options include monitoring and decontamination, therefore underscoring the need for novel pharmacological treatments. The industry sponsor/partner for this collaboration is Avicanna Inc., a biopharmaceutical company solely devoted to the development of cannabinoid-based medicinal products since its inception. In partnership with Dr. Khokhar, with his extensive track-record in behavioural pharmacology, this collaboration aims to provide a deeper understanding of the neural basis of cannabis-induced toxicosis in pets as well as the potential utility of cannabis-derived compounds and formulations for aiding the treatment of cannabis-induced toxicosis in pets. The goal of this series of experiments is to first establish the behavioural and neural correlates of cannabis-toxicosis in a rat model, and then test the effects of cannabidiol and tetrahydrocannabivarin (both agents can counteract the effect of THC), both alone and in combination on THC-induced toxicosis. The specific aims for this study are as follows:
Aim 1: To determine the behavioural and neural correlates of acute high-dose THC exposure via edible and vapour routes of administration.
Aim 2: To determine whether cannabidiol or THCV treatment, either alone or in combination, reduce the magnitude of the behavioural and neural correlates of acute high-dose THC toxicosis.
The findings from these studies will be impactful since they will identify a potentially novel therapeutic avenue for reducing THC-induced toxicosis in pets, as well as establishing the neural correlates of THC-induced toxicosis.